uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
04 nov. 2020 10h46 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in November
04 nov. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
27 oct. 2020 07h05 HE
|
uniQure Inc.
~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease ~ ~ Top-Line Data from HOPE-B Pivotal Trial in Hemophilia B Expected Before Year End ~ ...
uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
13 oct. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
30 sept. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
25 sept. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
03 sept. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
26 août 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Aug. 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
30 juil. 2020 07h05 HE
|
uniQure Inc.
~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~ ~ Completed First Patient Dosing in...
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
24 juin 2020 16h05 HE
|
uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...